Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. (2021)

First Author: Adams RA
Attributed to:  Evaluating new healthcare technologies in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.21.01436

PubMed Identifier: 34516759

Publication URI: http://europepmc.org/abstract/MED/34516759

Type: Journal Article/Review

Volume: 39

Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Issue: 33

ISSN: 0732-183X